Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Equity Average (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Equity Average for 10 consecutive years, with $159.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average changed N/A to $159.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $159.8 million, a N/A change, with the full-year FY2023 number at $40.7 million, down 34.68% from a year prior.
  • Equity Average was $159.8 million for Q4 2025 at Crescent Biopharma, up from $127.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $159.8 million in Q4 2025 to a low of -$15.7 million in Q1 2025.
  • A 5-year average of $66.9 million and a median of $54.5 million in 2025 define the central range for Equity Average.
  • Biggest YoY gain for Equity Average was 1264.01% in 2025; the steepest drop was 146.73% in 2025.
  • Crescent Biopharma's Equity Average stood at $89.1 million in 2021, then tumbled by 48.9% to $45.5 million in 2022, then dropped by 6.68% to $42.5 million in 2023, then plummeted by 77.92% to $9.4 million in 2024, then skyrocketed by 1603.86% to $159.8 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Equity Average are $159.8 million (Q4 2025), $127.9 million (Q3 2025), and $54.5 million (Q2 2025).